Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

NCT02345226 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

881

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: FTC/RPV/TAF
DRUG: EFV/FTC/TDF Placebo
DRUG: EFV/FTC/TDF
DRUG: FTC/RPV/TAF Placebo

Sponsor

Gilead Sciences